Completed PHASE3 INTERVENTIONAL 2-arm NCT06107153

Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control

Sponsor: University of Basrah

Interventions Insulin Glargine 100 UNT/ML Pen Injector [Lantus] Pioglitazone 30mg Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg

Updated 6 times since 2023 Last updated: Mar 25, 2025 Started: Nov 1, 2023 Primary completion: Nov 1, 2024 Completion: Nov 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06107153, this PHASE3 trial focuses on Type2diabetes and remains completed. Sponsored by University of Basrah, it has been updated 6 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Apr 2025 — Sep 2025 [monthly]

Completed PHASE3

Status: Recruiting → Completed · Phase: NA → PHASE3
Sep 2024 — Apr 2025 [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
Feb 2024 — Jul 2024 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Nov 2023 — Feb 2024 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Basrah

Data source: University of Basrah

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Basra, Iraq